Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02710734 · ClinicalTrials.gov registry record · Phase 2
Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)
A Phase 2 study of Urothelial Carcinoma of the Bladder, sponsored by Fox Chase Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
- 4
- Study locations
NCT02710734 is a Phase 2 study of Urothelial Carcinoma of the Bladder that is active but no longer recruiting, run by Fox Chase Cancer Center. The registered enrollment target is 78 participants. The trial reports 4 study locations across 3 states.
The verdict
NCT02710734, a Phase 2 study of Urothelial Carcinoma of the Bladder, is active but no longer recruiting, sponsored by Fox Chase Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
- 4
- Study locations
Study Summary
The aim of this study is to evaluate a risk-adapted approach to the treatment of muscle invasive bladder cancer. Each baseline transuretheral resection of bladder tumor (TURBT) sample will be sequenced while proceeding with neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) chemotherapy. Based on the mutational profile and the post AMVAC TURBT findings, patients will be treated with active surveillance (experimental arm), or standard of care intravesicle therapy, chemoradiation or surgery. We hypothesize that this approach will lead to non-inferior metastasis-free survival at 2 years, while preserving the bladder and thus quality-of-life for a proportion of patients.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Doxorubicin
- DRUG Methotrexate
- RADIATION Intensity modulated radiation therapy (IMRT)
- DRUG Vinblastine
Study Locations (4)
Pennsylvania
- Sidney kimmel Cancer Center - Philadelphia
- Fox Chase Cancer Center - Philadelphia
District of Columbia
- Washington Cancer Institute at MedStar Washington Hospital Center - Washington D.C.
Maryland
- Johns Hopkins - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2016-02-24 |
| Est. Completion | 2034-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02710734
The ClinicalTrials.gov registry entry for NCT02710734 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urothelial Carcinoma of the Bladder appearing as the primary indexed condition, and to 5 interventions - of which Cisplatin is the first listed.
NCT02710734 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Pennsylvania, District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT02710734 about?
NCT02710734 is a clinical study titled "Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)". The aim of this study is to evaluate a risk-adapted approach to the treatment of muscle invasive bladder cancer. Each baseline transuretheral resection of bladder tumor (TURBT) sample will be sequenced while proceeding with neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplati...
What is the current status of trial NCT02710734?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2016-02-24. Estimated completion is 2034-02.
What conditions does trial NCT02710734 study?
This clinical trial studies the following conditions: Urothelial Carcinoma of the Bladder.
What interventions are being tested in trial NCT02710734?
The interventions under investigation include: Cisplatin (DRUG), Doxorubicin (DRUG), Methotrexate (DRUG), Intensity modulated radiation therapy (IMRT) (RADIATION), Vinblastine (DRUG).
Who is sponsoring clinical trial NCT02710734?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02710734 being conducted?
This trial has 4 study locations across District of Columbia, Maryland, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Carcinoma of the Bladder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.